| |||||||
| |||||||
| |||||||
| 1 | AN ACT concerning State government.
| ||||||
| 2 | Be it enacted by the People of the State of Illinois,
| ||||||
| 3 | represented in the General Assembly:
| ||||||
| 4 | Section 5. The Department of Public Health Powers and | ||||||
| 5 | Duties Law of the
Civil Administrative Code of Illinois is | ||||||
| 6 | amended by adding Section 2310-349 as follows: | ||||||
| 7 | (20 ILCS 2310/2310-349 new) | ||||||
| 8 | Sec. 2310-349. The Childhood Cancer Research Board. | ||||||
| 9 | (a) The Childhood Cancer Research Board is created as an | ||||||
| 10 | advisory board within the Department. The Board shall consist | ||||||
| 11 | of 11 members as follows: 2 members appointed by the President | ||||||
| 12 | of the Senate; one member appointed by the Minority Leader of | ||||||
| 13 | the Senate; 2 members appointed by the Speaker of the House of | ||||||
| 14 | Representatives; one member appointed by the Minority Leader of | ||||||
| 15 | the House of Representatives; 2 members appointed by the | ||||||
| 16 | Governor, one of whom shall be designated as chair of the Board | ||||||
| 17 | at the time of appointment; and 2 members appointed by the | ||||||
| 18 | Director. The Director, or his or her designee, shall serve as | ||||||
| 19 | an ex officio member of the Board. Members appointed under this | ||||||
| 20 | Section shall be experts in pediatric cancer or members of the | ||||||
| 21 | General Assembly; however, no appointing authority may appoint | ||||||
| 22 | more than one member of the General Assembly to serve during | ||||||
| 23 | the same term. For the purposes of this Section, an "expert in | ||||||
| |||||||
| |||||||
| 1 | pediatric cancer" is defined as a physician or scientist who | ||||||
| 2 | (i) holds a position of leadership in an internationally | ||||||
| 3 | recognized program of pediatric cancer research at the time of | ||||||
| 4 | his or her appointment, or (ii) is a fully tenured professor at | ||||||
| 5 | an institution of higher education. In addition, an expert in | ||||||
| 6 | pediatric cancer must possess at least one of the following | ||||||
| 7 | qualifications: | ||||||
| 8 | (1) a strong track record of publication; | ||||||
| 9 | (2) participation in a federally-funded pediatric | ||||||
| 10 | cancer research program; | ||||||
| 11 | (3) a leadership role in a national cancer research | ||||||
| 12 | society, including the American Society of Hematology, the | ||||||
| 13 | American Association of Cancer Research, or the American | ||||||
| 14 | Society of Clinical Oncology; and | ||||||
| 15 | (4) participation in a National Cancer Institute or | ||||||
| 16 | American Cancer Society study section. | ||||||
| 17 | The Board members shall serve one 2-year term. If a vacancy | ||||||
| 18 | occurs in the Board membership, the vacancy shall be filled in | ||||||
| 19 | the same manner as the initial appointment. | ||||||
| 20 | (b) Board members shall serve without compensation but may | ||||||
| 21 | be reimbursed for their reasonable travel expenses from funds | ||||||
| 22 | appropriated for that purpose. The Department shall provide | ||||||
| 23 | staff and administrative support services to the Board. | ||||||
| 24 | (c) The Board must review grant applications, make | ||||||
| 25 | recommendations and comments, and consult with the Department | ||||||
| 26 | of Public Health in making grants from amounts appropriated | ||||||
| |||||||
| |||||||
| 1 | from the Childhood Cancer Research Fund to public or private | ||||||
| 2 | not-for-profit entities for the purpose of conducting | ||||||
| 3 | childhood cancer research in accordance with Section 6z-93 of | ||||||
| 4 | the State Finance Act. | ||||||
| 5 | (d) Grants shall be awarded to research projects that fall | ||||||
| 6 | within the following categories: | ||||||
| 7 | (1) understanding the basic biology of specific | ||||||
| 8 | pediatric cancers using cellular and animal models; | ||||||
| 9 | (2) pre-clinical studies that translate basic | ||||||
| 10 | observations into novel diagnostics or therapeutic agents | ||||||
| 11 | specific to pediatric cancer; or | ||||||
| 12 | (3) support of Phase I clinical trials of new agents | ||||||
| 13 | developed at Illinois institutions. | ||||||
| 14 | (e) The Board shall make its recommendations to the | ||||||
| 15 | Department no later than March 1 of the year after the | ||||||
| 16 | application is received.
| ||||||